Anemia Control in Renal Transplant Recipients Receiving Continuous Erythropoietin Receptor Activator (C.E.R.A.) Treatment: The AnemiaTrans Study
Continuous erythropoietin receptor activator (C.E.R.A.) effectively enables anemia control in patients with chronic kidney disease, but little information is available in renal transplant recipients. The authors aimed to evaluate the effect of C.E.R.A. under clinical practice conditions on anemia control in renal transplant recipients.
This was a multicenter, retrospective, observational study carried out in adult renal transplant patients in the immediate posttransplant period and at late posttransplant period receiving C.E.R.A. in clinical practice. Patients’ data were retrieved from their medical charts at baseline and months 1, 3, and 6.
A total of 318 evaluable patients were enrolled into the study: 32 in the immediate posttransplant period and 286 at late posttransplant period (erythropoiesisstimulating agent [ESA]-naïve, n = 44; converting from other ESAs, n = 242). Patients in the immediate posttransplant period experienced a significant increase in hemoglobin (Hb) levels from baseline to month 1 (9.9±1.5 g/dL vs. 11.5±1.4 g/dL; P< 0.001). ESA-naïve patients showed increasing mean Hb levels from baseline to month 6 (10.1±0.7 g/dL vs. 11.7±1.0 g/dL; P < 0.001) and 94.7% achieved Hb ≥11 g/dL during the study. In patients converted from other ESAs, the percentage of patients with Hb between 11–13 g/dL was maintained from baseline to month 6 with no significant differences (61.0% vs. 62.4%). Mean monthly doses of C.E.R.A. at baseline were 134.4±56.4 μg, 81.3±28.1 μg, and 93.0±44.2 μg in immediate posttransplant, ESA-naïve, and converted patients, respectively. C.E.R.A. was well tolerated.
C.E.R.A. enables anemia control in renal transplant recipients, allowing target Hb levels to be achieved and maintained with doses even below those described in the Summary of Product Characteristics.
- Vanrenterghem Y. Anemia after kidney transplantation. Transplantation. 2009;87:1265–1267. CrossRef
- Chhabra D, Grafals M, Skaro AI, Parker M, Gallon L. Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol. 2008;3:1168–1174. CrossRef
- Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients-a prospective cohort study. Am J Transplant. 2007;7:818–824. CrossRef
- Winkelmayer WC, Chandraker A, Alan BM, Kramar R, Sunder-Plassmann G. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant. 2006;21:3559–3566. CrossRef
- Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002;13:1084–1090.
- Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol. 2003;14:462–468. CrossRef
- KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47:S11–S145. CrossRef
- de Francisco AL, Sulowicz W, Klinger M, et al; BA16260 Study Investigators. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006;60:1687–1696. CrossRef
- Provenzano R, Besarab A, Macdougall IC, et al; BA16528 Study Investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol. 2007;67:306–317.
- Macdougall IC, Walker R, Provenzano R, et al; ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008;3:337–347. CrossRef
- Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2011;26:3980–3986. CrossRef
- Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin. 2010;26:1083–1089. CrossRef
- Carrera F, Lok CE, de Francisco A, et al; PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009–4017. CrossRef
- Canaud B, Mingardi G, Braun J, et al; STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008;23:3654–3661. CrossRef
- Levin NW, Fishbane S, Canedo FV, et al; MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415–1421. CrossRef
- Locatelli F, Villa G, de Francisco AL, et al; BA16286 Study Investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23:969–979. CrossRef
- Carreño A, Campistol JM, Arias M, Morales JM, Pallardo L, Franco A. A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group). Am J Transplant. 2011;11:36.
- Minutolo R, Zamboli P, Chiodini P, et al. Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purif. 2010;30:186–194. CrossRef
- Mann JF, de Francisco A, Nassar G, Canaud B. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol. 2011;76:9–15.
- Locatelli F, Mann JF, Aldigier JC, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol. 2010;73:94–103.
- Anemia Control in Renal Transplant Recipients Receiving Continuous Erythropoietin Receptor Activator (C.E.R.A.) Treatment: The AnemiaTrans Study
Advances in Therapy
Volume 29, Issue 11 , pp 979-991
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- Clinical practice
- Continuous erythropoietin receptor activator
- Erythropoiesis-stimulating agents
- Erythropoiesis-stimulating agent-naïve
- Renal transplant recipients
- Industry Sectors
- Author Affiliations
- 1. Department of Nephrology, Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, S/N, 28040, Madrid, Spain
- 2. Department of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
- 3. Department of Nephrology, Hospital Clinic Barcelona, Barcelona, Spain
- 4. Department of Nephrology, Hospital Universitario 12 Octubre, Madrid, Spain
- 5. Department of Nephrology, Hospital Universitario Central de Asturias, Oviedo, Spain
- 6. Department of Nephrology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain
- 7. Department of Nephrology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
- 8. Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain
- 9. Department of Nephrology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain
- 10. Department of Nephrology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
- 11. Department of Nephrology, Hospital Universitario de La Princesa, Madrid, Spain
- 12. Department of Nephrology, Hospital Universitario Doctor Peset, Valencia, Spain
- 13. Department of Nephrology, Fundación Puigvert, Barcelona, Spain